QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.076505v1 313/1/216    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Claude-Geppert, P. A. Articles by Law, P.-Y. Search for Related Content PubMed PubMed Citation Articles by Claude-Geppert, P. A. Articles by Law, P.-Y.

CELLULAR AND MOLECULAR

Antagonist Efficacy in MORS196L Mutant Is Affected by the Interaction between Transmembrane Domains of the Opioid Receptor

Department of Pharmacology, Medical School, University of Minnesota, Minneapolis, Minnesota

In a previous study, we demonstrated that antagonists such as naloxone or naltrexone acted as full agonists at the µ-opioid receptor (MOR)/-opioid receptor (DOR) chimeric receptor (µ2, where the DOR sequence from the first extracellular loop to the carboxyl terminus was spliced to the MOR sequence) when a conserved serine residue in transmembrane 4 (TM4) was mutated to leucine. However, when Ser¹⁹⁶ in the TM4 of MOR was mutated to Leu, antagonists exhibited partial agonistic properties. Since molecular modeling studies suggested transmembrane movement during receptor activation, the observed partial agonistic properties could be due to TM1 and TM7 interaction. Hence, MOR/DOR chimeric mutant receptors with the MOR TM1 and TM7 sequence (µ₂µ₇S196L) or with the MOR TM1 and TM6/7 sequence (µ₂µ₆₇S196L) were constructed to test such a hypothesis. Using four tests of opioid receptor activation, we found that the opioid antagonists were full agonists in chimeric mutant receptor if the TM1 and TM7 were from different opioid receptors. Additionally, when two of the TM7 amino acid residues of MORS196L receptor mutants were mutated (T327A and C330S), resulting in a mutant receptor with DOR TM7 sequence, opioid antagonist naloxone exhibited full agonistic properties. These data suggest that the efficacy of opioid antagonists in the Ser¹⁹⁶ mutant can be affected by the interaction between TM1 and TM7.

Address correspondence to: Ping-Yee Law, Department of Pharmacology, Medical School, University of Minnesota, 6-120 Jackson Hall, 321 Church Street., S.E., Minneapolis, MN 55455-0217. E-mail: lawxx001{at}umn.edu

This article has been cited by other articles:

				S. L. Chen, H. I. Ma, J. M. Han, P. L. Tao, P. Y. Law, and H. H. Loh dsAAV type 2-mediated gene transfer of MORS196A-EGFP into spinal cord as a pain management paradigm PNAS, December 11, 2007; 104(50): 20096 - 20101. [Abstract] [Full Text] [PDF]

				Y. Qiu, H. H. Loh, and P.-Y. Law Phosphorylation of the {delta}-Opioid Receptor Regulates Its beta-Arrestins Selectivity and Subsequent Receptor Internalization and Adenylyl Cyclase Desensitization J. Biol. Chem., August 3, 2007; 282(31): 22315 - 22323. [Abstract] [Full Text] [PDF]

				H. Zhao, H. H. Loh, and P. Y. Law Adenylyl Cyclase Superactivation Induced by Long-Term Treatment with Opioid Agonist Is Dependent on Receptor Localized within Lipid Rafts and Is Independent of Receptor Internalization Mol. Pharmacol., April 1, 2006; 69(4): 1421 - 1432. [Abstract] [Full Text] [PDF]